QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NYSE:HAE

Haemonetics (HAE) Stock Forecast, Price & News

$86.48
+1.88 (+2.22%)
(As of 06/1/2023 ET)
Compare
Today's Range
$84.43
$86.62
50-Day Range
$76.08
$89.45
52-Week Range
$58.23
$91.39
Volume
236,596 shs
Average Volume
362,823 shs
Market Capitalization
$4.37 billion
P/E Ratio
38.78
Dividend Yield
N/A
Price Target
$103.17

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
19.3% Upside
$103.17 Price Target
Short Interest
Healthy
2.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
1.07mentions of Haemonetics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$191,992 Sold Last Quarter
Proj. Earnings Growth
11.55%
From $3.55 to $3.96 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

529th out of 1,980 stocks

Surgical & Medical Instruments Industry

57th out of 200 stocks


HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
StockNews.com Upgrades Haemonetics (NYSE:HAE) to Strong-Buy
Haemonetics Corporation: Premium Blood Play
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Haemonetics (NYSE:HAE) Releases FY 2024 Earnings Guidance
Barrington Reaffirms Their Buy Rating on Haemonetics (HAE)
2030, Blood Filtration Market Research
Haemonetics: Fiscal Q4 Earnings Snapshot
See More Headlines

HAE Price History

HAE Company Calendar

Last Earnings
2/07/2023
Today
6/01/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$103.17
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+20.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
12.10%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$5.10 per share
Book Value
$16.18 per share

Miscellaneous

Free Float
49,707,000
Market Cap
$4.32 billion
Optionable
Optionable
Beta
0.44

Social Links


Key Executives

  • Christopher A. SimonChristopher A. Simon
    President, Chief Executive Officer & Director
  • James C. Darecca
    Executive VP, Chief Financial & Accounting Officer
  • Anila LingamneniAnila Lingamneni
    Chief Technology Officer & Executive VP
  • Laurie A. MillerLaurie A. Miller
    Chief Human Resources Officer & Senior VP
  • David James Wilson
    President-Plasma Business Unit













HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year price targets for Haemonetics' shares. Their HAE share price forecasts range from $88.00 to $115.00. On average, they expect the company's stock price to reach $103.17 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2023?

Haemonetics' stock was trading at $78.65 at the beginning of 2023. Since then, HAE shares have increased by 8.7% and is now trading at $85.49.
View the best growth stocks for 2023 here
.

Are investors shorting Haemonetics?

Haemonetics saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,040,000 shares, a decrease of 21.2% from the April 15th total of 1,320,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is presently 3.2 days. Currently, 2.1% of the shares of the stock are sold short.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its earnings results on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier earned $305.30 million during the quarter, compared to the consensus estimate of $300.47 million. Haemonetics had a trailing twelve-month return on equity of 20.13% and a net margin of 9.87%. The business's revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.84 EPS.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2024 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $3.45-$3.75 for the period, compared to the consensus EPS estimate of $3.40. The company issued revenue guidance of $1.22 billion-$1.25 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.09%), Fisher Asset Management LLC (2.07%), Geode Capital Management LLC (1.87%), Royce & Associates LP (1.67%), Dimensional Fund Advisors LP (1.39%) and Boston Partners (1.32%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $85.49.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $4.32 billion and generates $1.17 billion in revenue each year. The medical instruments supplier earns $115.40 million in net income (profit) each year or $2.23 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 3,034 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -